NCT01788995 is a clinical trial in Ovarian Cancer, Peritoneal Neoplasms, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT01788995?

NCT01788995 is sponsored by Hoffmann-La Roche.

What condition does NCT01788995 study?

NCT01788995 studies Ovarian Cancer, Peritoneal Neoplasms.

Is NCT01788995 still recruiting?

NCT01788995 is currently completed. Last updated 3 January 2019.

Last reviewed 2019-01-03 · How we verify

NCT01788995

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer

Completed Last updated 3 January 2019

What this trial tests

trial in Ovarian Cancer, Peritoneal Neoplasms in 63 participants. Completed in 11 October 2018.

Timeline

15 October 2012

Primary endpoint
11 October 2018

11 October 2018

Quick facts

Lead sponsor	Hoffmann-La Roche
Status	Completed
Study type	OBSERVATIONAL
Enrollment	63
Start date	15 October 2012
Primary completion	11 October 2018
Estimated completion	11 October 2018
Sites	1 location across Austria

Conditions studied

Ovarian Cancer, Peritoneal Neoplasms — all drugs for Ovarian Cancer, Peritoneal Neoplasms →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer, Peritoneal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This non-interventional study will evaluate the routine use and the safety and efficacy of Avastin (bevacizumab) as first-line treatment in patients with advanced ovarian cancer (epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma). Newly diagnosed patients who are initiated on carboplatin/paclitaxel chemotherapy in combination with Avastin will be followed for up to 15 months of treatment and 12 months of follow-up.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
Tsibulak I, Polterauer S, Reinthaller A, Schauer C, et al · · 2022 · PMID 35146539 · DOI 10.1007/s00508-022-02005-2

Verify or expand the search:

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01788995 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 3 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01788995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing